REGN
Regeneron Pharmaceuticals · Health Care
2.3%
typical move (median |reaction| of last 8)
2026-10-27 pre · likely
next expected · estimated from pattern
19
scored events
Last eight reactions
2025-10-06 → 2026-10-06
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-10-06 | pre | +1.7% | 1.7% | +2.2% | n/a |
| 2026-07-30 | pre | +6.0% | 6.0% | +0.9% | +5.5% |
| 2026-07-06 | pre | -0.7% | 0.7% | +2.3% | +16.0% |
| 2026-04-29 | pre | -6.2% | 6.2% | +1.9% | -15.4% |
| 2026-04-08 | pre | +2.0% | 2.0% | -6.3% | -15.6% |
| 2026-01-30 | pre | -1.0% | 1.0% | +6.1% | +7.5% |
| 2025-10-28 | pre | +12.2% | 12.2% | -2.5% | +22.0% |
| 2025-10-06 | pre | -2.6% | 2.6% | -3.4% | +8.1% |
Source filings
2026-10-06 · 8-K press release
false 0000872589 0000872589 2026-10-01 2026-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Purs
2026-07-30 · 8-K press release
Regeneron Reports Second Quarter 2026 Financial and Operating Results • Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 • Dupixent ® global net sales (recorded by
2026-07-06 · 8-K press release
false 0000872589 0000872589 2026-07-06 2026-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Purs
2026-04-29 · 8-K press release
Regeneron Reports First Quarter 2026 Financial and Operating Results • First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025 • Dupixent ® global net sales (recorded by Sa
2026-04-08 · 8-K press release
false 0000872589 0000872589 2026-04-08 2026-04-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Purs
2026-01-30 · 8-K press release
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results • Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues incr
2025-10-28 · 8-K press release
Regeneron Reports Third Quarter 2025 Financial and Operating Results • Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 • Dupixent ® global net sales (recorded by Sa
2025-10-06 · 8-K press release
false 0000872589 0000872589 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Purs